Abstract
AS LIFE EXPECTANCY increases and the elderly population grows, clinicians can expect to see a larger number of elderly patients with cancer. Most prospective randomized studies that utilize combination chemotherapy exclude patients older than 65 years; therefore, the prognosis and cure rate of elderly patients with lymphoma remains unknown. Elderly lymphoma patients suffer both from excess treatment-related mortality and treatment-unrelated mortality. Known factors contributing to excess mortality are decreased organ/system endurance, increased co-morbid medical conditions, higher prevalence of second neoplasms, and lower remission rates. Thus, aggressive lymphoma management in the elderly is hampered by obstacles demanding from the clinician a thorough understanding of the interacting disease, as well as treatment and host variables affecting outcome.
Original language | English (US) |
---|---|
Pages (from-to) | 192-196 |
Number of pages | 5 |
Journal | Cancer Bulletin |
Volume | 47 |
Issue number | 3 |
State | Published - Jan 1 1995 |
ASJC Scopus subject areas
- Cancer Research